Kamalakar Chatla, Ph.D., is a technical development principal scientist at Genentech, specializing in genome engineering and next-generation sequencing (NGS). His work focuses on developing innovative approaches for mRNA and DNA therapeutics, contributing to advancements in cancer treatment and cell and gene therapies. With over 15 years of experience in molecular biology research, he is well versed in a wide range of molecular biology techniques and NGS methodologies, including short- and long-read sequencing technologies (Illumina, PacBio, ONT), as well as Hi-C, ChIP-seq, and RNA-seq. His work focuses on enabling cutting-edge technologies to drive progress in cell and gene therapies.